HOME >> BIOLOGY >> NEWS
New monoclonal antibody therapies offer significant survival advantage for breast cancer patients

Paris, France, Monday 31 October 2005 - Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage. These new findings were released at the 13th European Cancer Conference (ECCO) on the recommendation of the Independent Data Monitoring Committee.

The study in question, an international, multicentre, randomised, 3-arm trial is being conducted by the Breast International Group (BIG) in collaboration with the pharmaceutical company Roche AG, manufacturers of Herceptin. In total, 5,090 early breast cancer patients have been enrolled into this trial by the 478 participating institutions from Europe, Canada, South Africa, Israel, the Asia Pacific Region, Japan and Latin America. All women accrued had HER-2 positive breast cancer (either node negative or positive) and had completed at least four cycles of an acceptable (neo) adjuvant chemotherapy regimen. For women with hormone receptor positive disease, adjuvant endocrine therapy (most commonly tamoxifen) followed chemotherapy. The average age of study participants is 49 years.

The aim of this trial is to compare the effect of 1 year of Herceptin infusions, given every 3 weeks, with one year of simple observation, on survival primarily DFS but also overall survival (OS), relapse-free survival (RFS) and distant disease free survival (DDFS), as well as comparable assessment of overall and cardiac safety. The study also consists of a 2-year arm where 2 years of 3-weekly Herceptin is being compared with observation.

Results from the 1-year arm of the study, showcased at ECCO 13, show that Herceptin is associated with a significant improvement in DFS in this group of patients. The difference in Herceptin treated women was 85.8% compared to 77.4% of women on observati
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
31-Oct-2005


Page: 1 2 3

Related biology news :

1. Report calls for improved monoclonal antibodies against solid tumors
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. New antibody for EGFR causes lung cancer regression
4. A key antibody, IgG, links cells capture and disposal of germs
5. Research pinpoints West Nile virus antibody binding site
6. A single sugar found responsible for an antibodys ability to treat inflammation
7. Study shows how protein raises antibody output
8. Researchers link specific antibody presence to prevention of mother-to-baby HIV transmission
9. New study shows antibody-interleukin complexes stimulate immune responses
10. High resolution snapshots detail dynamics of a cocaine antibody
11. Immune substances may help antibody-based drugs fight cancer

Post Your Comments:
(Date:8/19/2014)... Research and Network-Level Science, , Imagine if we had ... ecosystems was responding to global changes in real time. ... coupled multiple decades of information about ecological responses to ... dozens of different ecosystem types. , In fact, ... (LTER) Network, which will soon celebrate its 35th anniversary. ...
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
(Date:8/19/2014)... today,s crocodiles colonised the seas during warm phases and ... Anglo-French study which establishes a link between marine crocodilian ... period of more than 140 million years. , ... Universit de Lyon, France and formerly from the University ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals that ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Engineering new bone growth 2Engineering new bone growth 3Evolution of marine crocodilians constrained by ocean temperatures 2
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/19/2014)... Sales Horizons, a leader in sales training, ... skills training course to help companies develop clinical ... spend the majority of their time on client sites ... physician practice – providing support and education to both ... Horizons believes clinical staff are and should be considered ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
Cached News: